| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 201.43 | 4.2% |
| Total Income | 202.49 | 4.3% |
| Expenditure | 187.32 | 4.8% |
| PBT | 15.17 | 1.7% |
| Net Profit | 10.01 | 8.7% |
| OPM | -3.19% | 0.49pp |
| NPM | 4.90% | 0.72pp |
| EPS | 3.80 | 8.4% |
Neogen Chemicals Ltd Reports 22% Revenue Growth to Rs. 201 Crore in Q3 FY25
02 Feb 2025 · 2 Feb 2025, 04:04 am
Summary
Neogen Chemicals Limited reported a robust financial performance for the quarter ended 31st December, 2024. The company's revenue grew by 22% to Rs. 201 crore, driven by volume growth in the base business and a healthy contribution from BuLi Chem. EBITDA increased by 71% to Rs. 34.6 crore, attributable to increased plant utilization, operational efficiencies, and lower employee costs. The battery chemicals arm, Neogen lonics, has commenced lithium salt exports, contributing to the topline. Neogen lonics is poised for substantial growth from the next financial year due to new capacities. The company's PAT stood at Rs. 10.0 crore, a growth of 844%.
Key Highlights
- 1
Revenue grew by 22% to Rs. 201 crore
- 2
EBITDA increased by 71% to Rs. 34.6 crore
- 3
Neogen lonics commenced lithium salt exports
- 4
Neogen lonics is poised for substantial growth from the next financial year
- 5
Profit after tax (PAT) stood at Rs. 10.0 crore, a growth of 844%
Management Comments
Mr. Haridas Kanani
Chairman & Managing Director, Neogen Chemicals
Our Q3 FY25 results demonstrate a robust recovery, with revenue up 22% and EBITDA up 71%. This growth is attributed to strong ramp-up in BuLi Chem and sustained growth in the base business volumes. Higher topline was achieved despite lower RM prices and resultant realizations across several product categories. New product launches and the pursuit of export opportunities drove the robust recovery. To mitigate the persistent slowdown in agrochemicals, we have strategically created additional end-use sectors such as semiconductors, flavors & fragrances and select industrial CSM opportunities. This highlights the adaptability of our agile business model, enabling us to meet evolving market needs and capitalize on emerging opportunities.
Informational and educational content only. Not investment advice.